<DOC>
	<DOCNO>NCT00251485</DOCNO>
	<brief_summary>This Phase II , open label , non-randomized study patient histologically pathologically confirm diagnosis stage IIIB/IV , EGFR+ adenocarcinoma colon rectum receive prior chemotherapy metastatic disease . Primary Study Endpoint : To assess response rate , progression-free survival , overall safety profile modify FOLFOX 6 plus cetuximab regimen first-line treatment patient metastatic colorectal cancer . Secondary Study Endpoint ( ) : To assess overall survival patient metastatic colorectal cancer receive first-line therapy modify FOLFOX 6 + cetuximab regimen .</brief_summary>
	<brief_title>A Phase II Trial Modified FOLFOX 6 Cetuximab First Line Treatment Metastatic Colorectal Cancer</brief_title>
	<detailed_description>The current treatment option metastatic colon cancer need improvement . The three-drug combination oxaliplatin 5-FU/LV first-line treatment metastatic colorectal cancer show significant increase response rate compare IFL ( irinotecan bolus 5-FU plus leucovorin ) IROX ( irinotecan plus oxaliplatin . Cetuximab show activity without irinotecan subject colorectal cancer refractory irinotecan alone.30,31 Cetuximab also show safe effective administer infusional 5-FU/folinic acid plus irinotecan . These result suggest addition cetuximab 5-FU/LV/oxaliplatin-based regimen ( FOLFOX ) use 1st line setting may lead development treatment option subject advanced colorectal cancer . This Phase II , open label , non-randomized study patient histologically pathologically confirm diagnosis stage IIIB/IV , EGFR+ adenocarcinoma colon rectum receive prior chemotherapy metastatic disease . Patients receive modify FOLFOX 6 regimen ( 5-FU , leucovorin , oxaliplatin ) every 2 week combination cetuximab give weekly . Patients evaluated response progression-free survival . Overall survival also evaluate , well safety profile regimen .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>1 . Patients must sign IRB approve informed consent . 2 . Patients histologically pathologically document , stage IIIB IV adenocarcinoma colon rectum . 3 . Patients disease amenable potentially curative resection ( i.e. , inoperable metastatic disease ) . 4 . Patients tumor EGFR + IHC stain . 5 . Patients ECOG Performance status 0 1 . 6 . Patients , 18 year old , must either child bear potential negative serum pregnancy test within 7 day prior registration . Patients consider child bear potential surgically sterile ( undergone hysterectomy , bilateral tubal ligation bilateral oophorectomy ) postmenopausal . 7 . Bone marrow function : absolute neutrophil count ( ANC ) &gt; = 1,500/uL , equivalent Common Terminology Criteria Adverse Events ( CTCAE , version 3 ) Grade 1 . Platelets &gt; = 100,000/uL ( CTCAE Grade 0 1 ) . 8 . Renal function : creatinine &lt; = 1.5 x institutional upper limit normal ( ULN ) , CTCAE Grade 1 . 9 . Hepatic function : bilirubin &lt; = 1.5 x ULN , CTCAE Grade 1 . AST &lt; = 2.5 x ULN , CTCAE Grade 1 . 1 . Patients receive prior chemotherapy metastatic disease . Prior adjuvant therapy 5FU/LV and/or irinotecan allow provide complete least 6 month prior enrollment study . 2 . Patents receive prior oxaliplatin . 3 . Patients receive prior cetuximab therapy specifically directly target EGF pathway . 4 . Patients acute hepatitis . 5 . Patients active uncontrolled infection . 6 . Patients significant history cardiac disease , i.e. , uncontrolled hypertension , unstable angina , congestive heart failure . 7 . Prior allergic reaction chimerized murine monoclonal antibody therapy . 8 . Any concurrent chemotherapy indicate study protocol investigational agent . 9 . Patients peripheral neuropathy &gt; grade 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>Metastatic 1st line colorectal cancer</keyword>
</DOC>